23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
---|---|---|---|---|
The Fight Against COVID19 | -1.11% | - | - | - |
^GSPC | +0.12% | +5.84% | +26.49% | +5602.44% |
Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 154.64 | +0.36 | +0.23% | 4:00 p.m. EDT | 6.09M | 7.46M | 372.17B |
ABBV | AbbVie Inc. | 166.42 | +2.07 | +1.26% | 4:00 p.m. EDT | 4.95M | 5.61M | 293.88B |
PFE | Pfizer Inc. | 28.64 | -0.28 | -0.97% | 4:01 p.m. EDT | 25.66M | 42.47M | 162.29B |
SNY | Sanofi | 48.67 | -0.15 | -0.31% | 4:00 p.m. EDT | 613.41k | 1.99M | 122.80B |
REGN | Regeneron Pharmaceuticals, Inc. | 982.29 | +14.31 | +1.48% | 4:00 p.m. EDT | 386.46k | 455.40k | 108.23B |
GSK | GSK plc | 44.98 | +0.10 | +0.22% | 4:00 p.m. EDT | 1.87M | 3.15M | 93.80B |
GILD | Gilead Sciences, Inc. | 67.72 | -0.14 | -0.21% | 4:00 p.m. EDT | 3.57M | 6.97M | 84.37B |
MRNA | Moderna, Inc. | 132.9 | +0.22 | +0.17% | 4:00 p.m. EDT | 2.70M | 3.82M | 50.93B |
TAK | Takeda Pharmaceutical Company Limited | 13.22 | -0.09 | -0.68% | 4:00 p.m. EDT | 1.01M | 1.65M | 41.70B |
BNTX | BioNTech SE | 90.61 | -2.37 | -2.55% | 4:00 p.m. EDT | 471.65k | 591.09k | 21.84B |
NVAX | Novavax, Inc. | 13.01 | -1.39 | -9.65% | 4:00 p.m. EDT | 13.76M | 12.78M | 1.92B |
VIR | Vir Biotechnology, Inc. | 9.73 | -0.20 | -2.01% | 4:00 p.m. EDT | 624.61k | 988.40k | 1.32B |
INO | Inovio Pharmaceuticals, Inc. | 12 | -0.79 | -6.18% | 4:00 p.m. EDT | 414.23k | 443.72k | 310.93M |
The biotech still hasn't lost momentum.
Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu